{"id":18794,"date":"2023-05-12T10:39:00","date_gmt":"2023-05-12T02:39:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18794"},"modified":"2024-12-19T10:41:52","modified_gmt":"2024-12-19T02:41:52","slug":"bayer-q1-2023-financial-report-sales-dip-amid-regional-challenges-and-covid-19-impact","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18794","title":{"rendered":"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact"},"content":{"rendered":"\n

Germany-based Bayer (ETR: BAYN<\/a>) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to \u20ac14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to \u20ac2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry.<\/p>\n\n\n\n

Pharmaceuticals Unit Sales and Regional Analysis<\/strong>
Bayer’s Pharmaceuticals unit experienced a 3.1% decline in sales, reaching \u20ac4.407 billion (USD 4.8 billion). Regional performance varied, with North American sales increasing by 5.4% to \u20ac1.11 billion, Latin America up by 3.7% to \u20ac221 million, and Europe\/Middle East\/Africa down by 2.1% to \u20ac1.771 billion. The Asia\/Pacific region saw a significant drop of 10.8% YOY to \u20ac1.305 billion (USD 1.4 billion), with China’s volume-based procurement (VBP) program identified as a significant factor. Notably, Xarelto (rivaroxaban) and Adalat (nifedipine) sales plummeted by 12.8% and 23.9%, respectively.<\/p>\n\n\n\n

COVID-19 Disruptions and Future Growth Prospects<\/strong>
The disruptions caused by COVID-19 have impacted Bayer’s prescription drug business. However, the company anticipates significant growth from this unit in the future, driven by the global rapid uptake of prostate cancer therapy Nubeqa (darolutamide) and kidney disease drug Kerendia (finerenone), as well as a robust radiology business.<\/p>\n\n\n\n

Global Consumer Health Sales Increase<\/strong>
Global Consumer Health sales increased by 4.1% YOY to \u20ac1.573 billion (USD 1.72 billion), with the Allergy & Cold and Dermatology categories leading the growth. Regional increases were seen in North America (\u20ac612 million, +1.2%), Latin America (\u20ac201 million, +16.1%), and Europe\/Middle East\/Africa (\u20ac516 million, +5.7%), while Asia-Pacific dropped by 1.2% YOY to \u20ac244 million.<\/p>\n\n\n\n

Leadership Transition and Pipeline Updates<\/strong>
As previously reported, former Roche Pharma CEO Bill Anderson joined Bayer’s management committee from April 1, 2023, and will officially take over as CEO from June 1, 2023. Current CEO Werner Baumann will retire at the end of May 2023. During Q1, Bayer discontinued four clinical trials affecting three products, including a bradykinin receptor B1 (BDKRB1) receptor antagonist and a P2X4 inhibitor, indicating a strategic realignment of the company’s pipeline.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[269,967,27],"class_list":["post-18794","post","type-post","status-publish","format-standard","hentry","category-company","tag-bayer","tag-etr-bayn","tag-finanical-reports"],"yoast_head":"\nBayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to \u20ac14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to \u20ac2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18794\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18794\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-12T02:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-19T02:41:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18794#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18794\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact\",\"datePublished\":\"2023-05-12T02:39:00+00:00\",\"dateModified\":\"2024-12-19T02:41:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18794\"},\"wordCount\":319,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Finanical Reports\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18794#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18794\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18794\",\"name\":\"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-05-12T02:39:00+00:00\",\"dateModified\":\"2024-12-19T02:41:52+00:00\",\"description\":\"Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to \u20ac14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to \u20ac2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18794#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18794\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18794#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact - Insight, China's Pharmaceutical Industry","description":"Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to \u20ac14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to \u20ac2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18794","og_locale":"en_US","og_type":"article","og_title":"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18794","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-05-12T02:39:00+00:00","article_modified_time":"2024-12-19T02:41:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18794#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18794"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact","datePublished":"2023-05-12T02:39:00+00:00","dateModified":"2024-12-19T02:41:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18794"},"wordCount":319,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bayer","ETR: BAYN","Finanical Reports"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18794#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18794","url":"https:\/\/flcube.com\/?p=18794","name":"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-05-12T02:39:00+00:00","dateModified":"2024-12-19T02:41:52+00:00","description":"Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to \u20ac14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to \u20ac2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18794#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18794"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18794#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18794"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18794\/revisions"}],"predecessor-version":[{"id":18795,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18794\/revisions\/18795"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}